ImmuPharma:Tim McCarthy Appointed as Non-executive Chairman

ImmuPharma PLC  the specialist drug discovery and development company, has announced the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect.

McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera, Harvard Healthcare and Expedeon Holdings. McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes.

Co-founding a number of healthcare and biotechnology companies, McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing, the company has said.

Commenting on Tim McCarthy’s appointment, Dimitri Dimitrou, Chief Executive Officer, said:

“We are delighted to have Tim join ImmuPharma as Chairman. This appointment represents a further strong addition to the Board. Tim’s commercial and industry background together with capital markets experience will be extremely valuable as ImmuPharma progresses its lead compound, LupuzorTM, through its pivotal Phase III trial, as well as providing guidance on ImmuPharma’s long term business strategy.”